

<i>Product Licence Number</i>	<i>Company Name</i>	<i>Product Name</i>	<i>Active Ingredients</i>	<i>Indications</i>	<i>Date of Authorisation</i>
01990/5017R	Frank Roberts (Herbal Dispensaries) Ltd	Roberts Avena Tablets	Avena Dry Extract 10:1 54-000 mg Zanthoxylum Bark Dry Extract 5:1 36-000 mg	A herbal remedy traditionally used where a gentle aid is required to combat the effects of over-work, mental fatigue and the strains of everyday life. General Sales List	16th May 1996
03262/0032	CIS (UK) Limited	Oncoscint CR103 (Sodium Acetate Buffer Solution)	Sodium Acetate Trihydrate BP 136 mg Glacial Acetic Acid BP QS	This solution is used to buffer Indium (<i>111</i> In) Chloride prior to radiolabelling CYT-103 Immunocojugate. It will not be administered directly to the patient. It is supplied as part of an Oncoscint diagnostic kit. Prescription Only Medicine	1st May 1996
03262/0033	CIS (UK) Limited	Oncoscint CR103, 1 mg/2 ml injection	Satumombab Pendetide HSE 1 mg	After radiolabelling with an indium (<i>111</i> In) chloride solution, OncoScint CR103 can be used in patients without detectable levels of antimurine antibodies (HAMA) as a diagnostic imaging agent to determine: The presence and extent of malignant disease in patients with proven colorectal adenocarcinoma or a high clinical suspicion of colorectal cancer recurrence. The extent of malignant disease in patients with a high clinical suspicion of ovarian cancer recurrence. Repeated doses of OncoScint CR103-In are indicated for HAMA-negative patients with a high clinical suspicion of carcinoma recurrence. Diagnostic images acquired with OncoScint CR103-In can provide useful additional information when used in conjunction with the results of other appropriate diagnostic tests. OncoScint CR103-In scan findings should be confirmed prior to deferring a surgical procedure which is otherwise indicated. Prescription Only Medicine	1st May 1996
03473/0015	Common Services Agency Ltd	Human Anti-D Immunoglobulin (250IU) liquid for I.M. Injection	Human Anti-D Immunoglobulin 250-000 IU	Human Anti-D Immunoglobulin is indicated in the following circumstances: (i) All Rh(D) negative women who deliver a Rh(D) positive infant. (ii) Maternal exposure of Rh(D) negative women to fetal red cells including:—Abortion, threatened, complete, incomplete, spontaneous.—Termination of pregnancy—Chorionic villus sampling—Amniocentesis—Antepartum haemorrhage—External version—Clinically substantial closed abdominal injuries—Intrauterine death—Ectopic pregnancy. (iii) Antenatal administration during pregnancy to Rh(D) negative women. (iv) Rh(D) Incompatible Blood Transfusion. Following accidental transfusion with Rh(D) positive blood the appropriate dosage should be based on the volume of red cells transfused: A dosage of 100-125 IU per 1 ml of transfused red cells is recommended. Human Anti-D immunoglobulin (250 IU) is also indicated in RH(D) incompatible blood transfusion where the volume of red cells transfused is low. Prescription Only Medicine	13th August 1996
03473/0022	Common Services Agency Ltd	Human Anti-D Immunoglobulin (500 IU) liquid for I.M. Injection	Human Anti-D Immunoglobulin 500-000 IU	Human Anti-D Immunoglobulin is indicated in the following circumstances: (i) All Rh(D) negative women who deliver a Rh(D) positive infant. (ii) Maternal exposure of Rh(D) negative women to fetal red cells including:—Abortion, threatened, complete, incomplete, spontaneous.—Termination of pregnancy—Chorionic villus sampling—Amniocentesis—Antepartum haemorrhage—External version—Clinically substantial closed abdominal injuries—Intrauterine death—Ectopic pregnancy. (iii) Antenatal administration during pregnancy to Rh(D) negative women. (iv) Human Anti-D immunoglobulin (500 IU) is also indicated in RH(D) incompatible blood transfusion where the volume of red cells transfused is low. Prescription Only Medicine	12th August 1996